ASSURE Defibrillator Study Meets Endpoints; All 303 Shock Events Converted
KMTS sits 65% above its 52-week low of $17.34.
Summary
Kestra's 21,612-patient ASSURE wearable defibrillator study met its primary safety and effectiveness endpoints, and the results are now published. The ACE-PAS analysis converted all 303 analyzable VT/VF shock events, with an inappropriate-shock rate of 0.0065 per patient-month and 94% of patients free of false alarms. That is the clinical evidence base the wearable cardioverter-defibrillator franchise needs to support adoption and reimbursement. Analysts lifted their average 12-month price target to $31.12, about 8% above the current $28.64, with consensus still Buy (eight Buy, one Hold). This lands after the September 14 8-K showing F1Q27 revenue of $31.0 million, up 60% year-over-year, and a raised FY27 outlook of $141 million — the clinical data reinforces that growth story rather than changing it. The offset remains the material weaknesses in internal controls disclosed in the September 10-Q.
At the time of this announcement, KMTS was trading at $28.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $17.34 to $31.99. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.